Novartis unveils positive data from studies of Zolgensma to treat SMA
Novartis has unveiled positive data from two studies of new gene therapy Zolgensma, which demonstrated that children with spinal muscular…
Precision and Personalized Medicine
Latest in
Precision and Personalized Medicine
Novartis’s SMA gene therapy Zolgensma to be available for NHS use
Novartis Gene Therapies’ Zolgensma (onasemnogene abeparvovec) will be available for use in the UK’s National Health Service (NHS) following recommendations…
By
SIRION and Sanofi partner on next-gen AAV gene therapy vectors
SIRION and Sanofi are partnering to develop improved AAV vectors to overcome some of the challenges facing gene therapies. The…
By
Bayer reports steady 2020 performance despite Covid-19 pandemic
German-headquartered pharma company Bayer has published its 2020 annual report. The report suggests that Bayer had a robust 2020 despite…
By
AbbVie and Caribou team up on next-gen off-the-shelf CAR-T therapies
AbbVie and Caribou are partnering to develop next-generation off-the-shelf CAR-T therapies for oncology indications. The collaboration centres around Caribou’s chRDNA…
By
TCR-T cell therapies for cancer: TScan raises $100m in Series C round
New and existing investors have supported TCR therapy-focused TScan with $100m in an oversubscribed Series C round. The money will…
By
Q&A with EY’s Adlai Goldberg: pandemic silver linings for cell and gene therapies
Like the rest of the pharma industry, cell and gene therapy companies have been disrupted by the pandemic. However, the…
By
Spotlight on Zolgensma: REGENXBIO receives $80m from Novartis for AAV vector
Novartis’s Zolgensma, a gene therapy for young children with SMA, leverages REGENXBIO’s NAV AAV9 vector to deliver the SMN gene…
By